首页 > 最新文献

Current Opinion in Gastroenterology最新文献

英文 中文
Radiofrequency ablation for the management of pancreatic mass lesions. 射频消融治疗胰腺肿块病变。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-04-25 DOI: 10.1097/MOG.0000000000000939
Ambreen A Merchant, Anna M Goebel, Field F Willingham

Purpose of review: Patients with pancreatic tumors may have limited treatment options. Pancreatic tumor ablation is a novel and emerging treatment modality which can now be performed using endoscopic ultrasound (EUS) guidance. This modality is well suited to guide energy delivery for radiofrequency ablation (RFA) and microwave ablation. These approaches provide minimally invasive, nonsurgical methods for delivering energy to ablate pancreatic tumors in situ . This review summarizes the current data and safety profile for ablation in managing pancreatic cancer and pancreatic neuroendocrine tumors.

Recent findings: RFA uses thermal energy to induce cell death by coagulative necrosis and protein denaturation. Studies have reported increased overall survival in patients with pancreatic tumors treated with EUS-guided RFA in a multimodality systemic approach and when used in palliative surgeries. Radiofrequency ablation may have corollary benefits in inducing an immune-modulatory effect. Tumor marker carbohydrate antigen 19-9 has been reported to decrease in response to RFA. Microwave ablation is an emerging modality.

Summary: RFA utilizes focal thermal energy to induce cell death. RFA has been applied through open, laparoscopic, and radiographic modalities. EUS-guided approaches are now allowing RFA and microwave ablation to be performed for pancreatic tumors in situ .

审查目的:胰腺肿瘤患者的治疗选择可能有限。胰腺肿瘤消融术是一种新兴的治疗方式,目前可在内镜超声(EUS)引导下进行。这种方式非常适合引导射频消融(RFA)和微波消融的能量输送。这些方法为原位消融胰腺肿瘤提供了微创、非手术的能量输送方法。本综述总结了目前消融治疗胰腺癌和胰腺神经内分泌肿瘤的数据和安全性:最近的研究结果:射频消融利用热能通过凝固性坏死和蛋白质变性诱导细胞死亡。研究报告显示,在多模式系统方法中使用 EUS 引导的射频消融术治疗胰腺肿瘤患者,以及在姑息性手术中使用射频消融术治疗胰腺肿瘤患者,总生存率均有所提高。射频消融在诱导免疫调节效应方面可能有必然的益处。据报道,肿瘤标志物碳水化合物抗原 19-9 对射频消融的反应会降低。微波消融是一种新兴的治疗方式:微波消融利用病灶热能诱导细胞死亡。RFA 已通过开腹、腹腔镜和放射模式应用。目前,在 EUS 引导下可对原位胰腺肿瘤进行 RFA 和微波消融。
{"title":"Radiofrequency ablation for the management of pancreatic mass lesions.","authors":"Ambreen A Merchant, Anna M Goebel, Field F Willingham","doi":"10.1097/MOG.0000000000000939","DOIUrl":"10.1097/MOG.0000000000000939","url":null,"abstract":"<p><strong>Purpose of review: </strong>Patients with pancreatic tumors may have limited treatment options. Pancreatic tumor ablation is a novel and emerging treatment modality which can now be performed using endoscopic ultrasound (EUS) guidance. This modality is well suited to guide energy delivery for radiofrequency ablation (RFA) and microwave ablation. These approaches provide minimally invasive, nonsurgical methods for delivering energy to ablate pancreatic tumors in situ . This review summarizes the current data and safety profile for ablation in managing pancreatic cancer and pancreatic neuroendocrine tumors.</p><p><strong>Recent findings: </strong>RFA uses thermal energy to induce cell death by coagulative necrosis and protein denaturation. Studies have reported increased overall survival in patients with pancreatic tumors treated with EUS-guided RFA in a multimodality systemic approach and when used in palliative surgeries. Radiofrequency ablation may have corollary benefits in inducing an immune-modulatory effect. Tumor marker carbohydrate antigen 19-9 has been reported to decrease in response to RFA. Microwave ablation is an emerging modality.</p><p><strong>Summary: </strong>RFA utilizes focal thermal energy to induce cell death. RFA has been applied through open, laparoscopic, and radiographic modalities. EUS-guided approaches are now allowing RFA and microwave ablation to be performed for pancreatic tumors in situ .</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"448-454"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9984555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic approaches to small intestinal strictures. 小肠狭窄的内窥镜治疗方法。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-06-22 DOI: 10.1097/MOG.0000000000000958
Munish Ashat, Rami El-Abiad, Mouen A Khashab

Purpose of review: Gastric outlet obstruction (GOO) occurs from benign or malignant causes. Historically, the treatment of benign strictures revolved around endoscopic balloon dilation, whereas, in the case of malignant strictures, the placement of self-expandable metallic stents was the focus. The advent of lumen-apposing metal stent has opened new horizons in addressing shortcomings of enteral stenting and surgical gastroenterostomies. The purpose of the review is to discuss the endoscopic approaches to small bowel strictures and to examine the supporting data behind each practice.

Recent findings: Given the risk and futility of balloon dilation for malignant strictures, enteral stenting is pursued in patients who are poor surgical candidates and with life expectancy less than 6 months. For patients with longer survival, surgical gastroenterostomy (S-GE) should be considered. Recent data have shown comparable technical and clinical success rates between EUS-gastroenterostomy and S-GE but with lower adverse event rate and hospital length of stay.

Summary: In recurrent benign strictures and malignant GOO, EUS-GE has recently gained momentum in providing an effective and a well tolerated alternative. Individualized therapy centered around the patient's prognosis and preference while factoring in the local expertise for the specific indication is vital.

审查目的:胃出口梗阻(GOO)可由良性或恶性原因引起。良性狭窄的治疗历来以内镜下球囊扩张为主,而恶性狭窄则以放置可自行扩张的金属支架为主。腔隙贴合金属支架的出现为解决肠道支架术和外科胃肠造口术的不足开辟了新天地。本综述旨在讨论小肠狭窄的内窥镜方法,并研究每种方法背后的支持数据:最近的研究结果:鉴于球囊扩张术治疗恶性狭窄的风险和徒劳性,肠道支架术适用于不适合手术且预期寿命少于 6 个月的患者。对于存活期较长的患者,应考虑采用外科胃肠造口术(S-GE)。最近的数据显示,EUS-胃肠造口术和 S-GE 的技术和临床成功率相当,但不良事件发生率和住院时间更短。摘要:对于复发性良性狭窄和恶性 GOO,EUS-GE 最近在提供一种有效且耐受性良好的替代方案方面获得了发展。根据患者的预后和偏好进行个体化治疗,同时考虑到当地对特定适应症的专业知识至关重要。
{"title":"Endoscopic approaches to small intestinal strictures.","authors":"Munish Ashat, Rami El-Abiad, Mouen A Khashab","doi":"10.1097/MOG.0000000000000958","DOIUrl":"10.1097/MOG.0000000000000958","url":null,"abstract":"<p><strong>Purpose of review: </strong>Gastric outlet obstruction (GOO) occurs from benign or malignant causes. Historically, the treatment of benign strictures revolved around endoscopic balloon dilation, whereas, in the case of malignant strictures, the placement of self-expandable metallic stents was the focus. The advent of lumen-apposing metal stent has opened new horizons in addressing shortcomings of enteral stenting and surgical gastroenterostomies. The purpose of the review is to discuss the endoscopic approaches to small bowel strictures and to examine the supporting data behind each practice.</p><p><strong>Recent findings: </strong>Given the risk and futility of balloon dilation for malignant strictures, enteral stenting is pursued in patients who are poor surgical candidates and with life expectancy less than 6 months. For patients with longer survival, surgical gastroenterostomy (S-GE) should be considered. Recent data have shown comparable technical and clinical success rates between EUS-gastroenterostomy and S-GE but with lower adverse event rate and hospital length of stay.</p><p><strong>Summary: </strong>In recurrent benign strictures and malignant GOO, EUS-GE has recently gained momentum in providing an effective and a well tolerated alternative. Individualized therapy centered around the patient's prognosis and preference while factoring in the local expertise for the specific indication is vital.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"356-361"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9922306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in digestive endoscopy: recent advances. 消化内镜检查中的人工智能:最新进展。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-07-17 DOI: 10.1097/MOG.0000000000000957
Jean-Francois Rey

Purpose of review: With the incessant advances in information technology and its implications in all domains of our life, artificial intelligence (AI) started to emerge as a need for better machine performance. How it can help endoscopists and what are the areas of interest in improving both diagnostic and therapeutic endoscopy in each part of the gastrointestinal (GI) tract. What are the recent benefits and clinical usefulness of this new technology in daily endoscopic practice.

Recent findings: The two main AI systems categories are computer-assisted detection 'CADe' for lesion detection and computer-assisted diagnosis 'CADx' for optical biopsy and lesion characterization. Multiple softwares are now implemented in endoscopy practice. Other AI systems offer therapeutic assistance such as lesion delineation for complete endoscopic resection or prediction of possible lymphanode after endoscopic treatment. Quality assurance is the coming step with complete monitoring of high-quality colonoscopy. In all cases it is a computer-aid endoscopy as the overall result rely on the physician. Video capsule endoscopy is the unique example were the computer conduct the device, store multiple images, and perform accurate diagnosis.

Summary: AI is a breakthrough in digestive endoscopy. Screening gastric and colonic cancer detection should be improved especially outside of expert's centers. Prospective and multicenter trials are mandatory before introducing new software in clinical practice.

审查目的:随着信息技术的不断进步及其对我们生活各个领域的影响,人工智能(AI)开始成为提高机器性能的一种需要。人工智能如何帮助内镜医师,在改善胃肠道(GI)各部位的诊断和治疗内镜方面有哪些值得关注的领域?这项新技术在日常内窥镜操作中有哪些最新优势和临床实用性:计算机辅助检测 "CADe "用于病变检测,"计算机辅助诊断""CADx "用于光学活检和病变特征描述。目前,多种软件已在内窥镜检查中得到应用。其他人工智能系统还提供治疗辅助,如为内镜下完整切除术划定病灶,或预测内镜治疗后可能出现的淋巴结。质量保证是对高质量结肠镜检查进行全面监控的下一步。在所有情况下,这都是一种计算机辅助内窥镜检查,因为整体结果取决于医生。视频胶囊内窥镜检查就是一个独特的例子,它由计算机控制设备、存储多幅图像并进行精确诊断。总结:人工智能是消化内镜检查的突破性进展,胃癌和结肠癌的筛查应得到改进,尤其是在专家中心以外的地区。在将新软件引入临床实践之前,必须进行前瞻性和多中心试验。
{"title":"Artificial intelligence in digestive endoscopy: recent advances.","authors":"Jean-Francois Rey","doi":"10.1097/MOG.0000000000000957","DOIUrl":"10.1097/MOG.0000000000000957","url":null,"abstract":"<p><strong>Purpose of review: </strong>With the incessant advances in information technology and its implications in all domains of our life, artificial intelligence (AI) started to emerge as a need for better machine performance. How it can help endoscopists and what are the areas of interest in improving both diagnostic and therapeutic endoscopy in each part of the gastrointestinal (GI) tract. What are the recent benefits and clinical usefulness of this new technology in daily endoscopic practice.</p><p><strong>Recent findings: </strong>The two main AI systems categories are computer-assisted detection 'CADe' for lesion detection and computer-assisted diagnosis 'CADx' for optical biopsy and lesion characterization. Multiple softwares are now implemented in endoscopy practice. Other AI systems offer therapeutic assistance such as lesion delineation for complete endoscopic resection or prediction of possible lymphanode after endoscopic treatment. Quality assurance is the coming step with complete monitoring of high-quality colonoscopy. In all cases it is a computer-aid endoscopy as the overall result rely on the physician. Video capsule endoscopy is the unique example were the computer conduct the device, store multiple images, and perform accurate diagnosis.</p><p><strong>Summary: </strong>AI is a breakthrough in digestive endoscopy. Screening gastric and colonic cancer detection should be improved especially outside of expert's centers. Prospective and multicenter trials are mandatory before introducing new software in clinical practice.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"397-402"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9922836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
G-POEM for gastroparesis: past, present and future. 治疗胃痉挛的 G-POEM:过去、现在和未来。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-05-11 DOI: 10.1097/MOG.0000000000000950
Ishaan Vohra, Harishankar Gopakumar, Douglas G Adler

Purpose of review: Gastroparesis is a chronic debilitating condition with rising incidence and healthcare burden. As abdominal surgeries, diabetes, viral infections and autoimmune diseases become more prevalent, gastroparesis will continue to upsurge. Conservative treatment options for gastroparesis are limited by their side effects and short-term efficacy. Gastric endoscopic pyloromyotomy (G-POEM) is a novel incisionless endosurgical technique with excellent long-term outcomes. This review is in time, as the demand for G-POEM will continue to escalate.

Recent findings: This review encompasses the conservative and nonconservative treatment options for gastroparesis. G-POEM is a nonconservative treatment option, and the aim of this review is to discuss the variations in technique of G-POEM, short-term and long-term clinical efficacy of G-POEM and adverse events associated with it.

Summary: G-POEM has high technical and clinical success with minimal adverse events. G-POEM outcomes are similar or superior when compared with other treatment options for refractory gastroparesis. G-POEM is being widely adopted and will become the preferred treatment choice in patients with refractory gastroparesis.

审查目的:胃瘫是一种使人衰弱的慢性疾病,发病率和医疗负担不断上升。随着腹部手术、糖尿病、病毒感染和自身免疫性疾病的流行,胃瘫的发病率将继续上升。胃瘫的保守治疗方案因其副作用和短期疗效而受到限制。胃内镜幽门切开术(G-POEM)是一种新型的无切口内外科技术,具有良好的长期疗效。由于对 G-POEM 的需求将继续攀升,因此本综述的发布恰逢其时:本综述涵盖了胃痉挛的保守和非保守治疗方案。G-POEM 是一种非保守治疗方案,本综述旨在讨论 G-POEM 技术的差异、G-POEM 的短期和长期临床疗效以及与之相关的不良反应。与其他治疗难治性胃瘫的方法相比,G-POEM 的疗效相似或更优。G-POEM 正在被广泛采用,并将成为难治性胃瘫患者的首选治疗方法。
{"title":"G-POEM for gastroparesis: past, present and future.","authors":"Ishaan Vohra, Harishankar Gopakumar, Douglas G Adler","doi":"10.1097/MOG.0000000000000950","DOIUrl":"10.1097/MOG.0000000000000950","url":null,"abstract":"<p><strong>Purpose of review: </strong>Gastroparesis is a chronic debilitating condition with rising incidence and healthcare burden. As abdominal surgeries, diabetes, viral infections and autoimmune diseases become more prevalent, gastroparesis will continue to upsurge. Conservative treatment options for gastroparesis are limited by their side effects and short-term efficacy. Gastric endoscopic pyloromyotomy (G-POEM) is a novel incisionless endosurgical technique with excellent long-term outcomes. This review is in time, as the demand for G-POEM will continue to escalate.</p><p><strong>Recent findings: </strong>This review encompasses the conservative and nonconservative treatment options for gastroparesis. G-POEM is a nonconservative treatment option, and the aim of this review is to discuss the variations in technique of G-POEM, short-term and long-term clinical efficacy of G-POEM and adverse events associated with it.</p><p><strong>Summary: </strong>G-POEM has high technical and clinical success with minimal adverse events. G-POEM outcomes are similar or superior when compared with other treatment options for refractory gastroparesis. G-POEM is being widely adopted and will become the preferred treatment choice in patients with refractory gastroparesis.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"390-396"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9931051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endotherapy in pediatric pancreatitis. 小儿胰腺炎的内部疗法
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-07-17 DOI: 10.1097/MOG.0000000000000955
Nicholas Norris, David M Troendle

Purpose of review: Some children with acute recurrent and chronic pancreatitis stand to benefit from therapeutic endoscopic interventions. The purpose of this review is to summarize specific endoscopic therapies used for these conditions and highlight areas of future research.

Recent findings: Multicenter collaboration and consortium efforts have provided more data now than ever on the technical outcomes and safety of therapeutic endoscopic procedures for pancreatitis in children. Indications are growing but more research is needed to help guide patient selection.

Summary: Advanced endoscopic procedures including endoscopic retrograde cholangiopancreatography, endoscopic-ultrasound guided therapies, and single-operator pancreatoscopy may be used in patients with acute recurrent or chronic pancreatitis to manage pancreatic duct obstruction or local complications including pseudocysts and walled-off necrosis. Patient and procedural factors differ between adults and children. Access to these procedures for younger children is growing, and technical outcomes and adverse event rates appear similar between adults and children.

审查目的:一些患有急性复发性和慢性胰腺炎的儿童可从内窥镜治疗干预中获益。本综述旨在总结治疗这些疾病的特定内镜疗法,并强调未来的研究领域:多中心合作和联合努力提供了比以往更多有关儿童胰腺炎内镜治疗手术的技术成果和安全性的数据。摘要:先进的内镜手术包括内镜逆行胰胆管造影术、内镜超声引导疗法和单人胰腺镜检查,可用于急性复发性或慢性胰腺炎患者,以治疗胰管梗阻或假性囊肿和壁脱性坏死等局部并发症。成人和儿童的患者和手术因素各不相同。年幼儿童接受此类手术的机会越来越多,成人和儿童的技术结果和不良事件发生率似乎相似。
{"title":"Endotherapy in pediatric pancreatitis.","authors":"Nicholas Norris, David M Troendle","doi":"10.1097/MOG.0000000000000955","DOIUrl":"10.1097/MOG.0000000000000955","url":null,"abstract":"<p><strong>Purpose of review: </strong>Some children with acute recurrent and chronic pancreatitis stand to benefit from therapeutic endoscopic interventions. The purpose of this review is to summarize specific endoscopic therapies used for these conditions and highlight areas of future research.</p><p><strong>Recent findings: </strong>Multicenter collaboration and consortium efforts have provided more data now than ever on the technical outcomes and safety of therapeutic endoscopic procedures for pancreatitis in children. Indications are growing but more research is needed to help guide patient selection.</p><p><strong>Summary: </strong>Advanced endoscopic procedures including endoscopic retrograde cholangiopancreatography, endoscopic-ultrasound guided therapies, and single-operator pancreatoscopy may be used in patients with acute recurrent or chronic pancreatitis to manage pancreatic duct obstruction or local complications including pseudocysts and walled-off necrosis. Patient and procedural factors differ between adults and children. Access to these procedures for younger children is growing, and technical outcomes and adverse event rates appear similar between adults and children.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"416-420"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9931880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 DOI: 10.1097/MOG.0000000000000964
{"title":"Editorial introductions.","authors":"","doi":"10.1097/MOG.0000000000000964","DOIUrl":"https://doi.org/10.1097/MOG.0000000000000964","url":null,"abstract":"","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"v"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9923518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of deep learning and radiomics approaches for pancreatic cancer diagnosis from medical imaging. 从医学影像诊断胰腺癌的深度学习和放射组学方法综述。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-07-18 DOI: 10.1097/MOG.0000000000000966
Lanhong Yao, Zheyuan Zhang, Elif Keles, Cemal Yazici, Temel Tirkes, Ulas Bagci

Purpose of review: Early and accurate diagnosis of pancreatic cancer is crucial for improving patient outcomes, and artificial intelligence (AI) algorithms have the potential to play a vital role in computer-aided diagnosis of pancreatic cancer. In this review, we aim to provide the latest and relevant advances in AI, specifically deep learning (DL) and radiomics approaches, for pancreatic cancer diagnosis using cross-sectional imaging examinations such as computed tomography (CT) and magnetic resonance imaging (MRI).

Recent findings: This review highlights the recent developments in DL techniques applied to medical imaging, including convolutional neural networks (CNNs), transformer-based models, and novel deep learning architectures that focus on multitype pancreatic lesions, multiorgan and multitumor segmentation, as well as incorporating auxiliary information. We also discuss advancements in radiomics, such as improved imaging feature extraction, optimized machine learning classifiers and integration with clinical data. Furthermore, we explore implementing AI-based clinical decision support systems for pancreatic cancer diagnosis using medical imaging in practical settings.

Summary: Deep learning and radiomics with medical imaging have demonstrated strong potential to improve diagnostic accuracy of pancreatic cancer, facilitate personalized treatment planning, and identify prognostic and predictive biomarkers. However, challenges remain in translating research findings into clinical practice. More studies are required focusing on refining these methods, addressing significant limitations, and developing integrative approaches for data analysis to further advance the field of pancreatic cancer diagnosis.

综述的目的:胰腺癌的早期准确诊断对于改善患者预后至关重要,而人工智能(AI)算法有可能在胰腺癌的计算机辅助诊断中发挥重要作用。在这篇综述中,我们旨在提供人工智能领域最新的相关进展,特别是深度学习(DL)和放射组学方法,用于使用计算机断层扫描(CT)和磁共振成像(MRI)等横断面成像检查诊断胰腺癌:本综述重点介绍了应用于医学成像的深度学习技术的最新发展,包括卷积神经网络(CNN)、基于变压器的模型和新型深度学习架构,这些架构侧重于多类型胰腺病变、多器官和多肿瘤分割,以及纳入辅助信息。我们还讨论了放射组学的进展,如改进的成像特征提取、优化的机器学习分类器以及与临床数据的整合。此外,我们还探讨了在实际环境中利用医学成像实施基于人工智能的胰腺癌诊断临床决策支持系统。摘要:深度学习和放射组学与医学成像在提高胰腺癌诊断准确性、促进个性化治疗规划以及确定预后和预测性生物标志物方面已显示出强大的潜力。然而,将研究成果转化为临床实践仍面临挑战。需要进行更多的研究,重点是完善这些方法,解决明显的局限性,并开发数据分析的综合方法,以进一步推动胰腺癌诊断领域的发展。
{"title":"A review of deep learning and radiomics approaches for pancreatic cancer diagnosis from medical imaging.","authors":"Lanhong Yao, Zheyuan Zhang, Elif Keles, Cemal Yazici, Temel Tirkes, Ulas Bagci","doi":"10.1097/MOG.0000000000000966","DOIUrl":"10.1097/MOG.0000000000000966","url":null,"abstract":"<p><strong>Purpose of review: </strong>Early and accurate diagnosis of pancreatic cancer is crucial for improving patient outcomes, and artificial intelligence (AI) algorithms have the potential to play a vital role in computer-aided diagnosis of pancreatic cancer. In this review, we aim to provide the latest and relevant advances in AI, specifically deep learning (DL) and radiomics approaches, for pancreatic cancer diagnosis using cross-sectional imaging examinations such as computed tomography (CT) and magnetic resonance imaging (MRI).</p><p><strong>Recent findings: </strong>This review highlights the recent developments in DL techniques applied to medical imaging, including convolutional neural networks (CNNs), transformer-based models, and novel deep learning architectures that focus on multitype pancreatic lesions, multiorgan and multitumor segmentation, as well as incorporating auxiliary information. We also discuss advancements in radiomics, such as improved imaging feature extraction, optimized machine learning classifiers and integration with clinical data. Furthermore, we explore implementing AI-based clinical decision support systems for pancreatic cancer diagnosis using medical imaging in practical settings.</p><p><strong>Summary: </strong>Deep learning and radiomics with medical imaging have demonstrated strong potential to improve diagnostic accuracy of pancreatic cancer, facilitate personalized treatment planning, and identify prognostic and predictive biomarkers. However, challenges remain in translating research findings into clinical practice. More studies are required focusing on refining these methods, addressing significant limitations, and developing integrative approaches for data analysis to further advance the field of pancreatic cancer diagnosis.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"436-447"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9945537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls. 胰腺外分泌功能不全的评估和管理:珍珠和陷阱。
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-05-11 DOI: 10.1097/MOG.0000000000000951
Mitchell L Ramsey, Phil A Hart, Christopher E Forsmark

Purpose of review: The diagnosis and management of exocrine pancreatic dysfunction (EPD) can be challenging. EPD classically results from conditions that cause loss of pancreatic acinar cell function and decreased digestive enzyme production. However, several conditions may contribute to signs or symptoms of EPD with otherwise normal pancreatic exocrine function. A thoughtful approach to considering these conditions, along with their specific therapies, can guide a tailored management approach.

Recent findings: An EPD severity classification schema has been proposed, which emphasizes a shift towards a more restrictive prescription of pancreas enzyme replacement therapy (PERT) for patients with milder EPD. In contrast, PERT use has been associated with a measurable survival benefit among individuals with EPD and pancreatic cancer, so the prescription of PERT may be more liberal in this population. Recent publications in the cystic fibrosis population offer pearls guiding the titration and optimization of PERT.

Summary: Among individuals with severe EPD, PERT is an effective therapy. Among individuals with milder EPD, although PERT is effective, there may be opportunities to provide additional and potentially more effective therapies.

审查目的:胰腺外分泌功能障碍(EPD)的诊断和治疗具有挑战性。胰腺外分泌功能障碍通常是由导致胰腺针叶细胞功能丧失和消化酶分泌减少的疾病引起的。然而,在胰腺外分泌功能正常的情况下,有几种情况可能会导致 EPD 的体征或症状。对这些疾病及其具体疗法进行深思熟虑的考虑,可以指导量身定制的管理方法:最近的研究结果:已经提出了一种 EPD 严重程度分类模式,该模式强调对 EPD 较轻的患者采用限制性较强的胰腺酶替代疗法(PERT)处方。与此相反,在 EPD 和胰腺癌患者中,PERT 的使用与可测量的生存获益相关,因此在这一人群中,PERT 的处方可能更为宽松。摘要:在重度 EPD 患者中,PERT 是一种有效的治疗方法。在 EPD 较轻的患者中,虽然 PERT 有效,但仍有机会提供其他可能更有效的疗法。
{"title":"Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls.","authors":"Mitchell L Ramsey, Phil A Hart, Christopher E Forsmark","doi":"10.1097/MOG.0000000000000951","DOIUrl":"10.1097/MOG.0000000000000951","url":null,"abstract":"<p><strong>Purpose of review: </strong>The diagnosis and management of exocrine pancreatic dysfunction (EPD) can be challenging. EPD classically results from conditions that cause loss of pancreatic acinar cell function and decreased digestive enzyme production. However, several conditions may contribute to signs or symptoms of EPD with otherwise normal pancreatic exocrine function. A thoughtful approach to considering these conditions, along with their specific therapies, can guide a tailored management approach.</p><p><strong>Recent findings: </strong>An EPD severity classification schema has been proposed, which emphasizes a shift towards a more restrictive prescription of pancreas enzyme replacement therapy (PERT) for patients with milder EPD. In contrast, PERT use has been associated with a measurable survival benefit among individuals with EPD and pancreatic cancer, so the prescription of PERT may be more liberal in this population. Recent publications in the cystic fibrosis population offer pearls guiding the titration and optimization of PERT.</p><p><strong>Summary: </strong>Among individuals with severe EPD, PERT is an effective therapy. Among individuals with milder EPD, although PERT is effective, there may be opportunities to provide additional and potentially more effective therapies.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"428-435"},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9945543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoluminal bariatric and metabolic therapies: state-of-the-art. 腔内减肥和代谢疗法:最新技术。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-07-13 DOI: 10.1097/MOG.0000000000000967
Nader Bakheet, Dilhana Badurdeen, Adrian Sartoretto, Vivek Kumbhari

Purpose of review: The aim of this review is to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoluminal bariatric and metabolic procedures.

Recent findings: The landscape of endoluminal devices and techniques for treating obesity has expanded significantly, with FDA-approved therapies currently available to patients with a body mass index values as high as 50 kg/m 2 . Although notable advancements have been made in this area, there is a need for further emphasis to be placed on the metabolic improvements resulting from these therapies, in addition to the conventional focus on weight loss outcomes. Some of these procedures are now FDA approved for the treatment of metabolic disease as opposed to weight loss. To achieve the most favorable results, it is imperative that all endoluminal interventions are combined with a moderately intensive diet and lifestyle program lasting at least 12 months.

Summary: Endoluminal metabolic and bariatric therapy represents a bridge between lifestyle counseling, pharmaceutical interventions, and the most efficacious treatment for obesity, bariatric surgery. By virtue of its minimally invasive approach, this therapy may be an appealing option for patients who are ineligible for, or averse to, bariatric surgery and who have experienced suboptimal outcomes or unable to afford medical treatments. Furthermore, these interventions may be particularly beneficial in the early stages of obesity.

综述的目的:本综述旨在介绍该领域的现状、最新进展,并描述这些腔内减肥和代谢手术的临床效果:用于治疗肥胖症的腔内设备和技术的范围已大大扩展,目前经 FDA 批准的疗法适用于体重指数值高达 50 kg/m 2 的患者。虽然这一领域已经取得了显著的进步,但除了传统的关注减肥效果外,还需要进一步强调这些疗法对新陈代谢的改善作用。目前,美国食品及药物管理局(FDA)已批准其中一些程序用于治疗代谢疾病,而非减肥。摘要:腔内代谢和减肥疗法是生活方式咨询、药物干预和最有效的肥胖症治疗方法--减肥手术之间的桥梁。这种疗法采用微创方式,对于不符合减肥手术条件或不愿意接受减肥手术的患者,以及疗效不理想或无力负担医疗费用的患者来说,可能是一种颇具吸引力的选择。此外,这些干预措施可能对肥胖症的早期阶段特别有益。
{"title":"Endoluminal bariatric and metabolic therapies: state-of-the-art.","authors":"Nader Bakheet, Dilhana Badurdeen, Adrian Sartoretto, Vivek Kumbhari","doi":"10.1097/MOG.0000000000000967","DOIUrl":"10.1097/MOG.0000000000000967","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review is to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoluminal bariatric and metabolic procedures.</p><p><strong>Recent findings: </strong>The landscape of endoluminal devices and techniques for treating obesity has expanded significantly, with FDA-approved therapies currently available to patients with a body mass index values as high as 50 kg/m 2 . Although notable advancements have been made in this area, there is a need for further emphasis to be placed on the metabolic improvements resulting from these therapies, in addition to the conventional focus on weight loss outcomes. Some of these procedures are now FDA approved for the treatment of metabolic disease as opposed to weight loss. To achieve the most favorable results, it is imperative that all endoluminal interventions are combined with a moderately intensive diet and lifestyle program lasting at least 12 months.</p><p><strong>Summary: </strong>Endoluminal metabolic and bariatric therapy represents a bridge between lifestyle counseling, pharmaceutical interventions, and the most efficacious treatment for obesity, bariatric surgery. By virtue of its minimally invasive approach, this therapy may be an appealing option for patients who are ineligible for, or averse to, bariatric surgery and who have experienced suboptimal outcomes or unable to afford medical treatments. Furthermore, these interventions may be particularly beneficial in the early stages of obesity.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"362-369"},"PeriodicalIF":2.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9922835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic therapy for gastroesophageal reflux disease: where are we, where are we going? 胃食管反流病的内镜治疗:我们在哪里,我们要去哪里?
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-09-01 Epub Date: 2023-07-20 DOI: 10.1097/MOG.0000000000000968
Muhammad Haseeb, Christopher C Thompson

Purpose of review: Gastroesophageal reflux disease (GERD) is the most common chronic condition with increasing prevalence in the Western world. Despite medical therapy, a considerable proportion of patients continue to experience symptoms, thus fueling the demand for minimally invasive GERD treatment options. This review will assess the currently available endoscopic approaches by analyzing their outcomes data, indication for use and limitations.

Recent findings: With increasing evidence of the safety and efficacy of endoscopic therapies, recent guidelines and consensus society documents have updated their recommendations for the endoscopic treatment of GERD. In this review, we have comprehensively assessed the current landscape of endoscopic approaches for the treatment of GERD and provided insight into future directions.

Summary: Endoscopic therapies for GERD show promise as new treatments emerge and existing therapies evolve into safer and more reproducible options. They are well positioned to cater to a large subset of the population suffering from chronic condition of GERD.

综述目的:胃食管反流病(GERD)是最常见的慢性疾病,在西方国家患病率不断上升。尽管进行了药物治疗,但仍有相当一部分患者继续出现症状,从而推动了对微创GERD治疗方案的需求。这篇综述将通过分析其结果数据、使用指征和局限性来评估目前可用的内窥镜方法。最近的发现:随着越来越多的证据表明内镜治疗的安全性和有效性,最近的指南和共识社会文件更新了他们对GERD内镜治疗的建议。在这篇综述中,我们全面评估了内镜下GERD治疗方法的现状,并对未来的发展方向提供了见解。摘要:随着新疗法的出现和现有疗法发展成为更安全、更可重复的选择,GERD的内镜治疗显示出了前景。他们能够很好地满足患有胃食管反流病的一大部分人群的需求。
{"title":"Endoscopic therapy for gastroesophageal reflux disease: where are we, where are we going?","authors":"Muhammad Haseeb, Christopher C Thompson","doi":"10.1097/MOG.0000000000000968","DOIUrl":"10.1097/MOG.0000000000000968","url":null,"abstract":"<p><strong>Purpose of review: </strong>Gastroesophageal reflux disease (GERD) is the most common chronic condition with increasing prevalence in the Western world. Despite medical therapy, a considerable proportion of patients continue to experience symptoms, thus fueling the demand for minimally invasive GERD treatment options. This review will assess the currently available endoscopic approaches by analyzing their outcomes data, indication for use and limitations.</p><p><strong>Recent findings: </strong>With increasing evidence of the safety and efficacy of endoscopic therapies, recent guidelines and consensus society documents have updated their recommendations for the endoscopic treatment of GERD. In this review, we have comprehensively assessed the current landscape of endoscopic approaches for the treatment of GERD and provided insight into future directions.</p><p><strong>Summary: </strong>Endoscopic therapies for GERD show promise as new treatments emerge and existing therapies evolve into safer and more reproducible options. They are well positioned to cater to a large subset of the population suffering from chronic condition of GERD.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"39 5","pages":"381-389"},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9922837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1